Terms ending in 2042
Every in-force patent on Actelion Pharmaceuticals Ltd's record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,951,097 | Methods of Treating Multiple Sclerosis In force · High confidence | Vanda Pharmaceuticals Inc. | In force | High confidence | |
| US 12,357,616 | Methods of Treating Multiple Sclerosis In force · High confidence | Vanda Pharmaceuticals Inc. | In force | High confidence | |
| US 12,485,119 | Methods of Treating Pulmonary Arterial Hypertension In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Actelion Pharmaceuticals Ltd.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.